Literature DB >> 20526532

Regulation of Skp2 expression and activity and its role in cancer progression.

Chia-Hsin Chan1, Szu-Wei Lee, Jing Wang, Hui-Kuan Lin.   

Abstract

The regulation of cell cycle entry is critical for cell proliferation and tumorigenesis. One of the key players regulating cell cycle progression is the F-box protein Skp2. Skp2 forms a SCF complex with Skp1, Cul-1, and Rbx1 to constitute E3 ligase through its F-box domain. Skp2 protein levels are regulated during the cell cycle, and recent studies reveal that Skp2 stability, subcellular localization, and activity are regulated by its phosphorylation. Overexpression of Skp2 is associated with a variety of human cancers, indicating that Skp2 may contribute to the development of human cancers. The notion is supported by various genetic mouse models that demonstrate an oncogenic activity of Skp2 and its requirement in cancer progression, suggesting that Skp2 may be a novel and attractive therapeutic target for cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526532      PMCID: PMC5763972          DOI: 10.1100/tsw.2010.89

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  47 in total

1.  Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress.

Authors:  Szu-Wei Lee; Chien-Feng Li; Guoxiang Jin; Zhen Cai; Fei Han; Chia-Hsin Chan; Wei-Lei Yang; Bin-Kui Li; Abdol Hossein Rezaeian; Hong-Yu Li; Hsuan-Ying Huang; Hui-Kuan Lin
Journal:  Mol Cell       Date:  2015-02-26       Impact factor: 17.970

Review 2.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

3.  Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.

Authors:  J Wu; S-W Lee; X Zhang; F Han; S-Y Kwan; X Yuan; W-L Yang; Y S Jeong; A H Rezaeian; Y Gao; Y-X Zeng; H-K Lin
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

4.  Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis.

Authors:  He Shen; Nuo Yang; Alexander Truskinovsky; Yanmin Chen; Ashley L Mussell; Norma J Nowak; Lester Kobzik; Costa Frangou; Jianmin Zhang
Journal:  Mol Cancer Res       Date:  2018-09-20       Impact factor: 5.852

5.  Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.

Authors:  Arron Sikka; Manjinder Kaur; Chapla Agarwal; Gagan Deep; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

6.  Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.

Authors:  Kazuhiro Maki; Fusako Sugita; Yuka Nakamura; Ko Sasaki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

7.  Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells.

Authors:  Hsin-Ying Hsieh; Jeng-Jer Shieh; Chun-Jung Chen; Mu-Yun Pan; Shu-Yi Yang; Shin-Chang Lin; Jo-Shu Chang; Alan Yueh-Luen Lee; Chia-Che Chang
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 8.  Ubiquitination involved enzymes and cancer.

Authors:  Mei-juan Zhou; Fang-zhi Chen; Han-chun Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

9.  SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.

Authors:  Pegah Johansson; Jessie Jeffery; Fares Al-Ejeh; Renèe B Schulz; David F Callen; Raman Kumar; Kum Kum Khanna
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

Review 10.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.